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VaccineAfrican horse sickness virus (AHSV) is an Orbivirus within the Reoviridae family, spread by Culicoides spe-
cies of midges, which infects equids with high mortality, particularly in horses and has a considerable
impact on the equine industry. In order to control the disease, we previously described Entry
Competent Replication Abortive (ECRA) virus strains for each of the nine distinct AHSV serotypes and
demonstrated their potential as vaccines, first in type I interferon receptor (IFNAR-/-) knockout mice,
and then in ponies. In this report we have investigated whether or not a combination ECRA vaccine com-
prising nine vaccine strains as two different cocktails is as efficient in ponies and the duration of the
immunity triggered by ECRA vaccines. In one study, a group of ponies were vaccinated with a cocktail
of 4 vaccine strains, followed by a vaccination of the remaining 5 vaccine strains, mimicking the current
live attenuated vaccine regimen. In the second study, ponies were vaccinated with a single ECRA-AHSV
strain and monitored for 6 months. The first group of ponies developed neutralising antibody responses
against all 9 serotypes, indicating that no cross-serotype interference occurred, while the second group
developed robust neutralising antibody responses against the single serotype that were sustained at
the same level throughout a 6-month study. The results support our previous data and further validate
ECRA vaccines as a safe and efficacious replacement of current live vaccines.
 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
African horse sickness (AHS) is an arthropod transmitted viral
disease, most commonly infecting horses, donkeys, and other
equids. Infection can manifest in a number of distinct forms, the
most lethal of which is the pulmonary form with a fatality rate
of 95% in susceptible horses [1]. Early symptoms of this include
mild depression, sweating, and coughing, and progress to pul-
monary oedema, and respiratory distress in the terminal stages.
A cardiac form is characterised by high fever, conjunctivitis,
abdominal pain, shortness of breath, and subcutaneous oedema,
and has a fatality rate of between 50 and 70%. The most common
form in susceptible animals is a mixed form, which presents with
signs of both the pulmonary and cardiac forms. In contrast to
horses, donkeys generally experience a mild subclinical form,
which is generally non-lethal. Zebras rarely experience symptoms,and are considered the natural reservoir of the virus, with other
species believed to be incidental hosts [2].
Currently African horse sickness virus (AHSV) is endemic only
in sub-Saharan Africa. However, sporadic outbreaks have been
reported in North Africa, Pakistan, India, Spain, and Portugal,
and more recently in Thailand [3] and Malaysia [4]. Such out-
breaks have a severe economic impact on the local horse indus-
try due to both loss of livestock, and introduction of controls on
animal movement. More importantly, due to the changing distri-
bution of Culicoides midges, the key vector of AHSV, there is a
very real possibility that AHS will also spread to regions previ-
ously considered at low risk. This has already occurred for the
related bluetongue virus (BTV), which has recently spread into
Northern Europe [5,6]. Current vaccination strategies rely on
the use of a multivalent live attenuated vaccine, however this
is considered unsafe due to the potential for reversion and re-
assortment with wild-type strains, and has not been licenced
in Europe [7,8]. It is therefore essential to develop safer, more
effective vaccine strategies [9].
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with a genome of 10 dsRNA segments. The virus particle is made
up of 7 structural proteins organised in concentric layers forming
a double capsid. The outer capsid consists of highly variable VP2
and a less variable VP5, whilst the inner capsid, or core, consists
of two layers of protein, a surface layer of VP7 and an inner layer
VP3. The inner core surrounds the segmented RNA genome, and
the replication complex consisting of minor enzymatic proteins
VP1, VP4, and VP6 [10].
Nine distinct AHSV serotypes (AHSV1 to AHSV9) have been
described based on the outer capsid protein VP2, the determinant
of serotype that mediates virus entry into the host cells.
Consequently, several vaccine candidates have been generated in
recent years targeting VP2; however, as yet none have been
licenced [11–14].
Towards the aim of developing a safe and effective AHSV vac-
cine, we first generated replication abortive virus strains deficient
in minor protein VP6, essential for virus replication [15]. These VP6
deficient virus strains remained able to enter AHSV-susceptible
cells or inoculated animals, however are unable to replicate fully
due to their inability to synthesise progeny double-stranded RNA.
These Entry-Competent-Replication-Abortive (ECRA) strains
undergo a single round of protein synthesis and then replication
stops. Propagation of ECRA vaccine strains is achieved in a comple-
mentary cell line expressing a functional VP6 protein in trans. Lim-
iting the vaccine strains to a single round of protein expression
effectively induces innate immunity but eliminates the risk of vir-
aemia and thus minimises the possibility of re-assortment with
wild type strains [15–18]. In previous studies, ECRA strains of
AHSV were capable of inducing a protective immune response
when type I interferon receptor (IFNAR-/-) mice were immunized
with either an ECRA-AHSV1 or ECRA-AHSV4 vaccine strain and
then challenged with the homologous strain of virulent virus. No
vaccinated mice developed clinical symptoms upon challenge
and AHSV RNA replication was shown to be minimal. Further stud-
ies were undertaken in ponies, a natural host for the virus, which
were vaccinated with either a monovalent AHSV4 vaccine or a
cocktail containing ECRA-AHSV 1/4/6/8, in a prime and boost reg-
imen. Serology data demonstrated a strong immune response in all
vaccinated animals and the generation of high titre neutralising
antibodies against all included serotypes. During subsequent chal-
lenge studies with the virulent AHSV4 strain, no significant clinical
symptoms were observed in any of the vaccinated ponies, confirm-
ing the ECRA viruses as being capable of generating a protective
immune response consistent with the presence of neutralising
antibody [18]. Together these data demonstrate that ECRA-AHSV
strains serve as safe and effective vaccine candidates. However,
both studies were of relatively short duration despite the fact that
equines are typically kept for extended periods. The longevity of
the immune response elicited by such vaccines therefore is an
important yet currently undefined parameter. Similarly, the exten-
sion of the proof-of-principle already reported to include a vaccine
capable of protecting against all 9 serotypes without interference
or strain dominance in the observed immune response to each dif-
ferent serotype is an important dimension if the ECRA vaccines are
to be widely used. Here we report on both these aspects of AHSV
ECRA vaccines.
In one study, ponies were immunised with a multivalent ECRA-
AHSV vaccine against all 9 AHSV serotypes to determine the feasi-
bility of a multivalent ECRA-AHSV approach. In a second study,
ponies were inoculated with a monovalent ECRA-AHSV vaccine
and the immune responses generated by vaccination were moni-
tored for a period of six months. Both seroconversion and serotype
specific neutralisation assays were performed to assess the pres-
ence of an antibody response over the period of the studies. Addi-
tionally, limited cytokine assays were performed post vaccination3162to detect common markers of T-helper type 1 (Th1), T-helper type
2 (Th2), and T-regulator (Treg) responses. Our data extend the pre-
vious studies and show that ECRA vaccines meet many of the cri-
teria for use in the field to control AHS disease.2. Materials and method
2.1. Cells and viruses
BSR Cells (a subclone of BHK-21 cells) were maintained in Dul-
becco modified Eagle Medium (DMEM; Sigma) supplemented with
5% foetal bovine serum (FBS; Sigma). The stable cell line BSR-VP6
was grown in DMEM + 5% FBS supplemented with 7.5 mg/ml puro-
mycin (Sigma). Mammalian cell lines were cultured at 37 C in a 5%
CO2 humidified atmosphere.
Wild type AHSV serotypes 1 to 9 were kindly provided by S.
Zientara (ANSES, France). All AHSV serotypes were passaged once
in BSR cells, titrated, and used for subsequent experiments.2.2. Plasmids
The plasmids for the AHSV reverse genetics system have been
described previously. Protein expression plasmids were generated
by inserting the coding regions of the desired viral proteins into the
pCAG-PM vector. T7 plasmids carrying the full-length segments of
AHSV were generated in pUC19.
The AHSV1 S9 mutants (S9 multistop) containing 11 stop
codons through the s9 gene was created previously by gene assem-
bly [18].2.3. Recovery of entry competent replication abortive AHSV variants
VP6 deficient AHSV strains were generated as previously
described [18,19]. Briefly, BSR cells stably expressing the AHSV1
VP6 protein were transfected with pCAG plasmids expressing 4
AHSV1 proteins, VP1, VP3, VP4, and NS2, and subsequently trans-
fection with RNA transcripts of AHSV segments 1 to 8, 10, and
the AHSV1 S9 multistop mutant. ECRA AHSV mutants of each ser-
otype were produced by substitution of appropriate segments as
described previously [19]. Recovered virus was plaque-purified
and titred on BSR-VP6 cells.2.4. Preparation of vaccine cocktails
Early passage ECRA AHSV stocks (1–2 passages in BSR-VP6
cells) were amplified in BSR-VP6 cells at a MOI of 0.1 in antibiotic
free media, harvested when complete cytopathic effect was visible,
and titrated on BSR-VP6 cells. Cocktails were produced by combin-
ing 105–106 pfu of each ECRA-AHSV serotype, and supplementing
with 10% trehalose. Stocks were then frozen in liquid nitrogen
and stored at 80 C until vaccination. Mock vaccine doses were
prepared from an equivalent number of BSR-VP6 cells lysed by
sonication.2.5. Multivalent ECRA-AHSV vaccination of ponies
To test the multivalent ECRA-AHSV vaccine protocol 6 ponies
were purchased from a riding stable in Val-d’Oise, France. 5 of
the 6 were injected subcutaneously all 9 serotypes of ECRA-AHSV
in two sequential injections. Cocktail 1 (ECRA-AHSV 1/4/7/9) was
injected on day 0, and Cocktail 2 (ECRA-AHSV 2/3/5/6/8) was
injected on day 21, with each strain present at 5x106 pfu except
ECRA-AHSV2 which was slightly lower, 4x105 due to poor growth
of ECRA-AHSV2. The inoculation titre of each individual strain was
Table 1
RNA segment substitutions required for recovery of ECRA-AHSV strains for all 9
serotypes of AHSV. ECRA-AHSV1 serves as the parental strain for all ECRA-AHSV
viruses, with serotype specific substitutions in the structural proteins VP2, VP3, VP5,
and VP7, as required. Table modified from Lulla et al (2016) [18].
AHSV1 segment exchanged for serotype
specific segment
VP2 + VP5 VP7 VP3
ECRA-AHSV1*
ECRA-AHSV2 + + +
ECRA-AHSV3 + +
ECRA-AHSV4 + +
ECRA-AHSV5 + + +
ECRA-AHSV6 + + +
ECRA-AHSV7 + + +
ECRA-AHSV8 +
ECRA-AHSV9 +
*ECRA-AHSV1 serves as the parental strain for all ECRA-AHSV strains.
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ous studies [19] and current LAV strategies.
Serum and whole blood samples were collected from each ani-
mal weekly between day 0 and day 83. In addition, a single pony
was mock-vaccinated with lysate from uninfected cells. This study
was performed in strict accordance with the French guidelines
and recommendations on animal experimentation and welfare
(ComEth Anses/ENVA/UPEC, Ethics APAFiS number:
2,019,032,008,313,852 (#19849)).
2.6. Long term ECRA-AHSV vaccination of ponies
To determine the duration of ECRA-AHSV immunity 7 ponies
were purchased from a stud farm in Normandy, France. 6 of these
were injected subcutaneously with 107 Plaque Forming Units of
ECRA-AHSV 4 twice, once on day 0 and again on day 21, in line
with our previous studies [19]. The remaining pony was mock vac-
cinated with lysate of an equivalent number of uninfected cells.
Animals were inspected daily for the development of clinical signs,
and serum and whole blood samples were collected weekly from
each animal between days 0 and 173. This study was performed
in strict accordance with the French guidelines and recommenda-
tions on animal experimentation and welfare (ComEth Anses/
ENVA/UPEC, Ethics APAFiS number: 2017061311362547).
2.7. Clinical monitoring
Each group of ponies was monitored on a daily basis, up to
83 days after vaccination, for the development to AHSV clinical
signs as described previously [19].
2.8. Viraemia
Blood samples were taken every 7–14 days for a minimum of
85 days post vaccination. These were processed and analysed by
real-time AHSV RT-PCR as described PCR to detect viral replication
[19].
2.9. Serology of ECRA AHSV vaccine trials
Serum samples were analysed using a commercially available
competitive ELISA AHSV4 VP7 Antibody Test kit (ELISA Ingezim
AHSV Compaq) according to manufacturer’s instructions. To detect
neutralising antibody responses, virus neutralisation assays were
performed against virulent AHSV as described previously [19].
Long term immunity was determined at a 90% neutralisation
threshold and multivalent immunity at 50%.
2.10. Cytokine analysis
Cytokine levels were measured in the blood of vaccinated
ponies without prior antigenic stimulation at days 0 (prime), 10–
14, 21 (boost) and 31 post-vaccination by Luminex assay. Briefly,
plasma was prepared within 30 min of blood collection and stored
at 20 C until analysis. Cytokines were measured using the MILLI-
PLEX MAP Equine Cytokine/Chemokine Magnetic Bead Panel (Mer-
ck) used as recommended by the manufacturer for the detection of
IL2, 4, 6, 10, 17, TNFa and IFNc.
3. Results
3.1. Generation of ECRA AHSV cocktails
As in our previous work all of our VP6 deficient ECRA-AHSV vac-
cine strains were generated by reverse genetics in a AHSV1 VP63163complementary BSR cell line [18,19]. Each serotype was generated
separately by sequential transfection of 5 viral protein expression
vectors (VP1, VP3, VP4, NS1, NS2), followed by transfection of 10
capped T7 RNA transcripts of the AHSV genomic RNA segments,
of which the S9 had been replaced with S9 multistop. AHSV1
was used as the basis for all strains of ECRA AHSV, with various ser-
otype specific segments substituted, as described previously [18]
and shown in Table 1.
Multivalent cocktail vaccines were then produced based upon
phylogenetic analysis of VP2, with phylogenetically distant sero-
types combined [20]. The vaccine cocktail 1 contained ECRA AHSV
1, 4, 7, and 9, as these four serotypes are most distant from each
other whilst Cocktail 2 contained the remaining ECRA AHSV strains
2, 3, 5, 6, and 8. Each cocktail was formulated such that serotypes
in each cocktail shared a maximum of 51% sequence homology
within VP2, in an attempt to minimise intra-cocktail cross
reactivity.3.2. Assessment of the immune response to multivalent ECRA-AHSV
innoculation
To assess the ability of our complete ECRA-AHSV vaccination to
generate a protective antibody response, five ponies (Blue, Orange,
Green, Purple, and Red) were injected sequentially with the two
cocktail vaccines 21 days apart, as shown in Fig. 1a, alongside a
Control animal (Black) vaccinated with lysate from uninfected
cells. Vaccination with Cocktail 1 of four vaccine strains (ECRA-
AHSV 1/4/7/9) was performed on day 1, whilst the second immu-
nisation with Cocktail 2 of five vaccine strains (ECRA-AHSV
2/3/5/6/8) was performed on day 21, in line with our previous
ECRA-AHSV protocols [19], and live attenuated vaccine strategies.
Following inoculation, animals showed a marginal (<1C) in-
crease in temperature which lasted no more than 1 day and a mild
cutaneous reaction at the site of inoculation which lasted maxi-
mally for a few days. No other adverse clinical events were noted
throughout the full monitoring period of 83 days. These reactions
were consistent with previous observations of the ECRA vaccines
[18,19] and are consistent with innate immune responses triggered
by the initial inoculums. Importantly, no symptoms typical of
AHSV were noted in any animal at any time following vaccination.
Sera were collected from all ponies approximately every 7 days
(Fig. 1a) for the duration of the study to monitor antibody
responses to ECRA-AHSV in each animal using a standard AHSV
group-specific VP7 antigen ELISA Test (Fig. 1b). All animals showed
a low antibody response after inoculation with cocktail 1, which
increase upon inoculation with cocktail 2. Of the five ponies, four
(Orange, Green, Purple, and Red) had high levels of antibody pro-
Fig. 1. a. Time course of the multivalent AHSV Trial. b. Seroconversion of animals after multivalent ECRA-AHSV vaccination. Animals were vaccinated with 2 different ECRA-
AHSV cocktails 21 days apart, with ECRA-AHSV1/4/7/9 on day 0, and ECRA-AHSV2/3/5/6/8 on day 21. The induction of the immune response was monitored in vaccinated
animals by VP7 group specific competitive ELISA.
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maintaining these levels for the duration of experiment. The con-
trol animal showed no evidence of any VP7 antibody response.
To investigate whether the vaccinated ponies developed AHSV
serotype specific neutralising antibody responses, we used neutral-
isation assays to determine the titre of neutralising antibody
against virulent strains of all 9 serotypes (Fig. 2). Consistent with
our previous data, sera collected prior to the second vaccination
dose with the Cocktail 2, demonstrated minor evidence of serum
neutralisation against the serotypes of the Cocktail 1, the first vac-
cination dose. Nevertheless, all animals showed some evidence of
neutralising antibody compared to the control at day 20. Two
ponies Red and Purple, however, showed evidence of a stronger
response. Purple achieved an anti-AHSV4 titre of 16, whilst Red
generated neutralising antibodies to AHSV4 and AHSV9 at titres
32 and 16 respectively. By day 42, 21 days after inoculation with
Cocktail 2, all animals had developed detectable antibody
responses to all 9 AHSV serotypes, although the levels of neutralis-
ing antibodies produced against each serotype did vary between
animals. Overall ECRA-AHSV2 elicited the weakest neutralising
antibody response, with Purple pony achieving only a titre above
8. This is consistent with the lower titre of virus included in the
vaccine cocktail and was not, therefore, unexpected. Importantly,
little difference was observed in the titres of antibodies against
the other serotypes in Cocktail 2 compared to those in Cocktail 1.
This is important given that in our previous study peak antibody
production was achieved at 35 days, 14 days after a booster of
the same serotypes was given [19]. Note that all vaccinated ponies
demonstrated enhanced response to AHSV serotypes present in
Cocktail 1, after immunisation with Cocktail 2, although the extent
of boosting varies between ponies and serotypes. Each of the 5
vaccinated ponies showed enhanced neutralisation of AHSV1, with
titres rising from < 8 at day 20 to 32 at day 42 for Blue, Green,3164Purple, and Red, and from 8 to 64 for Orange. Additionally, all
vaccinated ponies apart from Red demonstrate enhancement in
the neutralising antibody responses to certain serotypes present
in Cocktail 1 (Blue to AHSV7 and AHSV9; Orange to AHSV7; Green
to AHSV4 and Purple, AHSV4 and AHSV7). Interestingly, several
ponies also achieved comparable enhanced titres against Cocktail
2 serotypes that were not included in the Cocktail 1 (Blue, to
AHSV6; Orange, to AHSV3 and AHSV6; Green, to AHSV3 and
AHSV8; Purple, to AHSV 8; and Red, to AHSV6 and AHSV8).
Together these data suggest a cross serotype priming/boosting-
like activity.
One important caveat to this study is that each cocktail con-
tained different compositions of serotypes, as such, each animal
was only vaccinated against each serotype once, however our data
demonstrate that multivalent vaccination with our ECRA-AHSV
strains remains a feasible possibility. The detection of neutralising
antibodies against all 9 serotypes in all vaccinated animals, albeit
to varying levels, suggests that there is minimal cross-serotype
interference between ECRA-AHSV strains, and that a vaccination
protocol containing all 9 ECRA vaccine strains should feasibly elicit
protective immunity to all AHSV serotypes. Importantly all animals
achieved specific antibody titres of at least 8, against all 9 sero-
types, equivalent to the lowest titre shown to be protective against
homologous serotype challenge in our previous study [19].
3.3. Long term assessment of the protective response to ECRA-AHSV
vaccination
Previously we have shown that vaccination of ponies with a
monovalent ECRA-AHSV, results in a protective immune response
against virulent virus challenge. To determine the duration of this
protection 6 ponies (Cyan, Pink, Lilac, Jade, Gold, and Brown) were
vaccinated with ECRA-AHSV4, alongside a mock control (Grey), in a
Fig. 2. Serum neutralisation activity in ponies after multivalent ECRA-AHSV vaccination. Neutralizing antibody titres of vaccinated animal sera were determined by serum
neutralisation assay 21 days after receipt of Cocktail 1, immediately prior to Cocktail 2, and at 42 days. Neutralising antibody was never detected in the serum of the control
animal indicated in Black.
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samples were collected regularly for 173 days, and serological
assays were performed to monitor the immune response.
The development of an immune response was initially moni-
tored by ELISA, detecting the group specific VP7 antigen (Fig. 3).
All vaccinated ponies had developed a high titre of antibodies
against VP7 (between 73% and 94% in a competitive ELISA), by
day 28, demonstrating that all animals were seroconverted. In 5
of the 6 vaccinated ponies (Cyan, Pink, Lilac, Gold, and Brown)Fig. 3. Seroconversion of animals after ECRA-AHSV4 Vaccination. The induction of th
competitive ELISA.
3165the antibody titre remained high for the duration of the study
(up to day 173 post vaccination). One vaccinated pony (Jade) did
show inconsistent antibody titres (between 48 and 73%) during
the experiment but VP7 antibody remained detectable throughout
the study. No anti-VP7 antibody was detected in any of the sera
collected from the control animal.
Serotype specific immunity was determined by serum neutral-
isation assay (Fig. 4). On day 21 vaccinated animals showed only
very low levels of neutralising antibodies, consistent with the verye immune response was monitored in vaccinated animals by VP7 group specific
Fig 4. Long term serum neutralisation activity of sera collected from ECRA-AHSV4
vaccinated ponies. Sera collected throughout the study were examined for serotype
specific neutralisation by serum neutralisation assay against AHSV serotype 4.
Titres are expressed as the reciprocal of the highest dilution that maintained 90%
neutralisation compared to the control animal in Grey.
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28 however, 1 week after the booster immunisation, all vaccinated
animals had developed AHSV4 specific neutralising antibody titres
above 64. Peak antibody titres were visible in all vaccinated ponies
between days 28 and 42. After 28 days animals Cyan and Jade
demonstrated a considerable drop in neutralising antibody, from
512 and 256 respectively, to 16 by the end of the study. Gold
demonstrated a less dramatic drop from 512 at day 28 to 64 on
day 173. In contrast the antibody titres of animals Pink, Lilac,
and Brown remained consistently high (above 128) for the dura-
tion of the study. Importantly neutralising antibody titres
remained above 8 in all vaccinated animals for the duration of
the study demonstrating that vaccination with our ECRA AHSV
strains is capable of eliciting a sustained protective neutralising
immune response.3.4. Cellular innate immunity in vaccinated animals
Usually inactivated vaccines induce a predominantly antibody -
T-helper type 2 (Th2) mediated response (Th2-driven) but fail to
activate T-helper type 1 (Th1) driven cellular immune responses
which are the key for the elimination of intracellular infections
[21]. This is in contrast to live-attenuated and vector vaccines
which elicit generally balanced Th1-Th2 immune responses. With
the aim to characterize the innate immune responses after ECRA-
AHSV4 vaccination and to analyze if ECRA-AHSV4 vaccines could
trigger Th1 and or Th2-mediated immune responses, cytokine
levels were analysed by quantitative Luminex (Fig. 5). Our data
showed that ECRA-AHSV4 prime-boost vaccination could indeed
induce Th1 cytokine levels significantly in three ponies: Gold and
Brown, IFNc protein at 10 and 21 days post vaccination (dpv)
and Lilac, TNFa protein at 21 and 31 dpv; Gold, at 10 dpv and
Th2 cytokines in two animals: Lilac, IL10-protein and Brown, IL4-
protein from 10 to 31dpv; while Th17, a cytokine induced during
T regulatory cell (Treg) activation, was secreted in ponies Jade
and Gold at days 10 and 31 post vaccination. Our results demon-
strate that ECRA-AHSV4 vaccines are capable of inducing both
Th1 and Th2 immune responses. Further, the induction of Treg
cytokine profiles in two ponies was associated with lower antibody
responses in these animals.
We also assessed the Th1 and Th2 responses of animals vacci-
nated with multivalent ECRA-AHSV vaccines of two different cock-
tails, thus each animal has been vaccinated only once with each
vaccine strain. Only few animals demonstrated induction of low
level of Th1-immune responses and only one animal, Blue, showed
increased TNFa secretion on day 31 post vaccinations (data not3166shown). However, none developed Th2 or Treg-mediated
responses. Note that the vaccine strains are different for prime
and boost doses. Altogether, these data are consistent with both
inactivated and live virus vaccine immune responses [21].4. Discussion
With the growing risk of AHSV spreading beyond its traditional
boundaries, there is a clear and present need for a safe and effec-
tive AHSV vaccine. Current vaccination strategies still rely on a live
attenuated vaccine (LAV) although issues with both safety and effi-
cacy have been identified [9]. First and foremost is the potential for
re-assortment between vaccine strains and infecting virus, allow-
ing reversion of the attenuated virus to virulence [7,8]. Whole
sequence analysis of AHSV isolates from outbreaks in Gambia
and South Africa provides clear evidence that vaccine derived
strains have gained enhanced virulence through such re-
assortment and have caused AHSV outbreaks. In addition, the lack
of complete serotype coverage within the live attenuated vaccine
has allowed the emergence of those strains not included. LAV
AHSV vaccines are given in two doses, the first containing Serotype
1, 3, and 4, and the second serotypes 2, 6, 7, and 8, and, omitting
serotypes 5 or 9 completely for reasons of safety and efficacy. How-
ever, their exclusion from the vaccine has led to their spread, with
outbreaks of both in the areas where LAV is used [9]. Furthermore,
the protection afforded by the LAV is not complete as vaccinated
horses are still able to experience a subclinical infection [22].
The use of inactivated AHSV has also been investigated as a
potential vaccination strategy [23]; however, the results from
these studies suggest that such a strategy is not yet feasible. In
the absence of a robust adjuvant, protection is variable, with only
a fraction of vaccinated animals developing a full protective
immune response. In addition, even in those animals which
respond positively to vaccination, immunity is slow to develop,
limiting the feasibility of using inactivated AHSV as an emergency
vaccine. Additionally, long term immunity is dependent on subse-
quent booster vaccinations, every 6–12 months [24]. With a robust
adjuvant inactivated AHSVmay serve as a viable vaccine candidate,
however the current drawbacks mean that a live attenuated vac-
cine remains the preferred approach. Another key concern with
inactivated vaccines, and also LAVs, is that their production
requires the handling and processing of live infectious virus.
Previously we demonstrated that ECRA AHSV vaccine strains,
severely attenuated by not being able to complete the replication
cycle, are nevertheless capable of eliciting a strong immune
response, protecting inoculated animals against subsequent expo-
sure [18,19]. All vaccinated animals seroconverted and developed
neutralising antibodies but the study was limited to a subset of
serotypes used for the vaccination. In the current study we have
shown that inoculation with ECRA AHSV strains of all serotypes
in two sequential cocktails elicits an immune response against all
9 AHSV serotypes, including neutralising antibodies. Importantly,
our study included AHSV serotype 5 which is excluded from the
LAV due to cross serotype interference, and subsequent failure to
elicit a protective immune response [9]. Our previous data pro-
vided proof-of-principle for a multivalent vaccine with minimal
risk of cross serotype interference, and the data presented here
shows that this is indeed the case for all AHSV serotypes.
Of note in this study, vaccination was performed using different
virus cocktails. In our previous studies, boosting was performed
with at least one serotype present in the priming vaccination, as
designed to achieve maximal levels of seroconversion and neutral-
ising antibody response [19]. However, it was possible that the
observed boosting effect was restricted to serotype specific anti-
body. In the current study however, a more general cross-
Fig. 5. Cytokine Analysis of ponies vaccinated with ECRA AHSV4. Sera collected throughout the study were examined for cytokine expression by Luminex Assay, to monitor
(a) Th1, (b) Th2, and (c) T.Reg. response.
E. Sullivan, S. Lecollinet, A. Kerviel et al. Vaccine 39 (2021) 3161–3168serotype boosting effect is apparent. Importantly, neutralising anti-
body titres were raised as part of a general increase in anti-AHSV
titre. Maximum antibody titre against all serotypes, regardless of
cocktail, was achieved after the second vaccination, in particular,
neutralising antibody against Cocktail 1 serotypes were almost
undetectable prior to the Cocktail 2 vaccination, but rose against
all 9 serotypes to reach almost comparable levels. This cross-
serotype enhancement is likely due to conserved sequences within
the VP2 and VP5 proteins of the various serotypes. Alternatively, it
could be a result of the shared structural elements within the ECRA-
AHSV strains, all of which have been produced by serotype specific
substitutions within the parental ECRA-AHSV1 strain [18].
Alongside the multivalent vaccine, we also examined the dura-
tion of ECRA-AHSV induced immunity against one selected sero-
type, AHSV 4. Vaccinated ponies were found to remain
seroconverted for the duration of the study, approximately
6 months, with high levels of neutralising antibody detectable
throughout. Given the lack of complete protection by the LAV,
and the need for 8 vaccinations over 6 years [9], an immunisation
schedule including fewer administrations would be a considerable
improvement.
As noted, a common drawback of inactivated vaccines is the
failure to trigger a complete immune response. Inactivated vacci-
nes typically elicit a strong Th2 response, with minimal Th1 activ-
ity. This results in the generation of neutralising antibodies, but
often fails to stimulate strong cellular immunity [21,25]. Whilst
non-replicative, the ECRA-AHSV virus strains reported here retain
the ability to enter cells and undergo a single round of protein
expression, with replication blocked at the assembly stage. This
means that infected cells develop the hallmarks of infections,
allowing the detection of the ECRA viruses, triggering of a cytokine
cascade, and induction of a T-cell mediated response. During the
ECRA-AHSV4 trial, four of the six ponies demonstrated increased
levels of Th1 cytokines post vaccination, with 3 showing an addi-
tional strong induction of Th2 cytokines. Together with the gener-
ation of high titres of neutralising antibody, these data lend
support to the hypothesis that ECRA-AHSV viruses are capable of
inducing a balanced immune response, featuring both antibody
and cellular activities.3167Ponies vaccinated with the multivalent vaccines demonstrated
a reduced cytokine response, both Th1 and Th2, when compared
to the monovalent trial. This is likely a result of each animal receiv-
ing only a single dose of each serotype overall. Antibody titres were
also lower, suggesting that more complex cocktails and or further
boosts may be necessary to achieve peak immunity. Ideally, future
protection trials would address this issue although these are neces-
sarily complicated as a result of the biosecurity required.
Given the continuing spread of Culicoides midges throughout
Europe, and accompanied emergence of the related Bluetongue
virus, there is a very real possibility that AHSV will soon follow
and spread into previously low risk areas. Together with the issues
with the current live attenuated vaccine strategies, there is an
urgent need for a safe and effective vaccine against AHSV. By per-
mitting cell entry and viral protein expression, ECRA-AHSV vaccine
strains have been generated that stimulate immune responses,
akin to a live attenuated vaccine, without the requirement for
adjuvants. However, unlike the live vaccine, our ECRA vaccine
strains do not replicate in non-complementary cells, and thus have
safety profiles more commonly associated with killed vaccines,
specifically the lack of reversion. Despite this, replication in the
complementing cell line is similar to the live virus, such that man-
ufacturing should be equivalent to both LAVs and inactivated vac-
cines. Additionally, production of our ECRA strains does not require
the handling of live virus.
The data presented here, together with our previous studies,
suggest that ECRA-AHSV strains can serve as safe effective vaccines
against all serotypes of AHSV.
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